Martin Rasmussen

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Radical Prostatectomy

Patient Reported Outcomes

Dna Damage Response

Top Venues

NPJ precision oncology

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Martin Rasmussen, Jacob Fredsøe, Paul Vinu Salachan, Marcus Pii Lunau Blanke, Stine Hesselby Larsen, Benedicte Parm Ulhøi, Jørgen Bjerggaard Jensen, Michael Borre, Karina Dalsgaard Sørensen
Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk. NPJ precision oncology 8 (1) (2024)
Martin Rasmussen, Jacob Fredsøe, Paul Vinu Salachan, Marcus Pii Lunau Blanke, Stine Hesselby Larsen, Benedicte Parm Ulhøi, Jørgen Bjerggaard Jensen, Michael Borre, Karina Dalsgaard Sørensen
Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk. NPJ precision oncology 8 (1) (2024)
Martin Rasmussen, Jacob Fredsøe, Paul Vinu Salachan, Marcus Pii Lunau Blanke, Stine Hesselby Larsen, Benedicte Parm Ulhøi, Jørgen Bjerggaard Jensen, Michael Borre, Karina Dalsgaard Sørensen
Stroma-specific gene expression signature identifies prostate cancer subtype with high recurrence risk. NPJ precision oncology 8 (1) (2024)
Eske N Glud, Martin Rasmussen, Yonghui Zhang, Ole A Mandrup, Paul Vinu Salachan, Michael Borre, Karina Dalsgaard Sørensen, Kenneth A Howard
Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 × anti-PSMA bispecific design. British journal of cancer 127 (12) (2022)
Malene Blond Ipsen, Ea Marie Givskov Sørensen, Emil Aagaard Thomsen, Simone Weiss, Jakob Haldrup, Anders Dalby, Johan Palmfeldt, Peter Bross, Martin Rasmussen, Jacob Fredsøe, Søren Klingenberg, Mads R Jochumsen, Kirsten Bouchelouche, Benedicte Parm Ulhøi, Michael Borre, Jacob Giehm Mikkelsen, Karina Dalsgaard Sørensen
A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer. Oncogene 41 (37) (2022)